Tasks
The EpSSG Pathology committee leads on the histological classification of sarcomas with systematic review of all sarcomas enrolled on the different clinical studies and trials. The aims of histological review are:
- improving the diagnostic reproducibility among the countries, especially for rare entities
-providing uniform reports with collection of data (morphologic, molecular and immunohistochemical) important for future analyses.
In the current FAR-RMS trial, the pathology committee has a critical role, in creating a repository of virtual slides of all rhabdomyosarcomas enrolled in the trial, This is of fundamental importance for the histological-molecular correlation, and for identifying novel clinically significant subtypes.
The Pathology Committee closely collaborates with the Biology Committee in order to identify potential morphologic/immunohistochemical surrogates of molecular alterations important for future therapeutic strategies.
Members of the committee have also contribute to the First New WHO classificationof paediatric soft tissue tumors and the IC3R committee to define diagnostic dataset for sarcomas
The EpSSG Pathology committee leads on the histological classification of sarcomas with systematic review of all sarcomas enrolled on the different clinical studies and trials. The aims of histological review are:
- improving the diagnostic reproducibility among the countries, especially for rare entities
-providing uniform reports with collection of data (morphologic, molecular and immunohistochemical) important for future analyses.
In the current FAR-RMS trial, the pathology committee has a critical role, in creating a repository of virtual slides of all rhabdomyosarcomas enrolled in the trial, This is of fundamental importance for the histological-molecular correlation, and for identifying novel clinically significant subtypes.
The Pathology Committee closely collaborates with the Biology Committee in order to identify potential morphologic/immunohistochemical surrogates of molecular alterations important for future therapeutic strategies.
Members of the committee have also contribute to the First New WHO classificationof paediatric soft tissue tumors and the IC3R committee to define diagnostic dataset for sarcomas
Contact information chair
Dr. Edmund Cheesman
Department of Paediatric Histopathology, Manchester University NHS Foundation Trust
Manchester, UK
Department of Paediatric Histopathology, Manchester University NHS Foundation Trust
Manchester, UK
| Name | Country | Hospital |
|---|---|---|
| Current Members | ||
| Edmund Cheesman | UK | Department of Paediatric Histopathology, Manchester University NHS Foundation Trust |
| Rita Alaggio | Italy | Servizio Anatomia Patologica, Bambino Gesù Children's Hospital, Rome |
| Anna Kelsey | UK | Department of Paediatric Histopathology, Manchester University NHS Foundation Trust |
| Laura Hiemcke-Jiwa /Flucke Uta | Netherlands | Princess Máxima Center for pediatric oncology, Utrecht |
| Marie Karanian | France | Centre Léon Bérard, département d'anatomopathologie |
| Svetlana Tafjord | Norway | Department of Pathology, Oslo University Hospital, Rikshospitalet |
| Marta Garrido Pontnou | Spain | Department of Pathology, Hospital Universitari Vall d'Hebron, Barcelona |
| Luisa Santoro | Italy | Istituto di Anatomia Patologica, University of Padua |
| Osnat Sher | Israel | Bone and Soft Tissue Pathology Division, Sourasky Medical Center, Tel Aviv |
